| BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence M Xing, R Liu, X Liu, AK Murugan, G Zhu, MA Zeiger, S Pai, J Bishop Journal of clinical oncology 32 (25), 2718, 2014 | 753 | 2014 |
| TERT Promoter Mutations and Their Association with BRAF V600E Mutation and Aggressive Clinicopathological Characteristics of Thyroid Cancer X Liu, S Qu, R Liu, C Sheng, X Shi, G Zhu, AK Murugan, H Guan, H Yu, ... The Journal of Clinical Endocrinology & Metabolism 99 (6), E1130-E1136, 2014 | 346 | 2014 |
| Mortality risk stratification by combining BRAF V600E and TERT promoter mutations in papillary thyroid cancer: genetic duet of BRAF and TERT promoter mutations in thyroid … R Liu, J Bishop, G Zhu, T Zhang, PW Ladenson, M Xing JAMA oncology 3 (2), 202-208, 2017 | 257 | 2017 |
| High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors Y Wang, P Hou, H Yu, W Wang, M Ji, S Zhao, S Yan, X Sun, D Liu, B Shi, ... The Journal of Clinical Endocrinology & Metabolism 92 (6), 2387-2390, 2007 | 208 | 2007 |
| Patient age–associated mortality risk is differentiated by BRAF V600E status in papillary thyroid cancer X Shen, G Zhu, R Liu, D Viola, R Elisei, E Puxeddu, L Fugazzola, ... Journal of Clinical Oncology 36 (5), 438, 2018 | 106 | 2018 |
| The prognostic value of tumor multifocality in clinical outcomes of papillary thyroid cancer F Wang, X Yu, X Shen, G Zhu, Y Huang, R Liu, D Viola, R Elisei, ... The Journal of Clinical Endocrinology & Metabolism 102 (9), 3241-3250, 2017 | 101 | 2017 |
| Association of TERT Promoter Mutation 1,295,228 C>T With BRAF V600E Mutation, Older Patient Age, and Distant Metastasis in Anaplastic Thyroid Cancer X Shi, R Liu, S Qu, G Zhu, J Bishop, X Liu, H Sun, Z Shan, E Wang, Y Luo, ... The Journal of Clinical Endocrinology & Metabolism 100 (4), E632-E637, 2015 | 96 | 2015 |
| The genetic duet of BRAF V600E and TERT promoter mutations robustly predicts loss of radioiodine avidity in recurrent papillary thyroid cancer J Liu, R Liu, X Shen, G Zhu, B Li, M Xing Journal of Nuclear Medicine 61 (2), 177-182, 2020 | 93 | 2020 |
| BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment Y Huang, S Qu, G Zhu, F Wang, R Liu, X Shen, D Viola, R Elisei, ... JNCI: Journal of the National Cancer Institute 110 (4), 362-370, 2018 | 76 | 2018 |
| BRAF V600E confers male sex disease-specific mortality risk in patients with papillary thyroid cancer F Wang, S Zhao, X Shen, G Zhu, R Liu, D Viola, R Elisei, E Puxeddu, ... Journal of clinical oncology 36 (27), 2787, 2018 | 63 | 2018 |
| Association of the T1799A BRAF mutation with tumor extrathyroidal invasion, higher peripheral platelet counts, and over-expression of platelet-derived growth factor-B in … Y Wang, M Ji, W Wang, Z Miao, P Hou, X Chen, F Xu, G Zhu, X Sun, Y Li, ... Endocrine-related cancer 15 (1), 183-190, 2008 | 61 | 2008 |
| REC8 is a novel tumor suppressor gene epigenetically robustly targeted by the PI3K pathway in thyroid cancer D Liu, X Shen, G Zhu, M Xing Oncotarget 6 (36), 39211, 2015 | 60 | 2015 |
| BRAF V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer Y Tao, F Wang, X Shen, G Zhu, R Liu, D Viola, R Elisei, E Puxeddu, ... The Journal of Clinical Endocrinology & Metabolism 106 (11), 3228-3238, 2021 | 44 | 2021 |
| Robust thyroid gene expression and radioiodine uptake induced by simultaneous suppression of BRAF V600E and histone deacetylase in thyroid cancer cells W Cheng, R Liu, G Zhu, H Wang, M Xing The Journal of Clinical Endocrinology & Metabolism 101 (3), 962-971, 2016 | 37 | 2016 |
| TERT promoter mutation determines apoptotic and therapeutic responses of BRAF-mutant cancers to BRAF and MEK inhibitors: Achilles Heel J Tan, R Liu, G Zhu, CB Umbricht, M Xing Proceedings of the National Academy of Sciences 117 (27), 15846-15851, 2020 | 33 | 2020 |
| Therapeutic targeting of FOS in mutant TERT cancers through removing TERT suppression of apoptosis via regulating survivin and TRAIL-R2 R Liu, J Tan, X Shen, K Jiang, C Wang, G Zhu, M Xing Proceedings of the National Academy of Sciences 118 (11), e2022779118, 2021 | 16 | 2021 |
| Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness T Zhang, X Shen, R Liu, G Zhu, J Bishop, M Xing Oncotarget 8 (1), 900, 2017 | 14 | 2017 |
| BzATP activates satellite glial cells and increases the excitability of dorsal root ganglia neurons in vivo Z Chen, C Zhang, X Song, X Cui, J Liu, NC Ford, S He, G Zhu, X Dong, ... Cells 11 (15), 2280, 2022 | 8 | 2022 |
| Stage ii differentiated thyroid cancer is a high-risk disease in patients< 45/55 years old Z Liu, X Shen, R Liu, G Zhu, T Huang, M Xing The Journal of Clinical Endocrinology & Metabolism 104 (11), 4941-4948, 2019 | 4 | 2019 |
| Genetic trio of BRAF and TERT alterations and rs2853669TT in papillary thyroid cancer aggressiveness R Liu, G Zhu, J Tan, X Shen, M Xing JNCI: Journal of the National Cancer Institute, djad265, 2023 | 2 | 2023 |
Rengyun LiuThe First Affiliated Hospital, Sun Yat-sen UniversityVerified email at mail.sysu.edu.cn
